A.AndriantsitohainaR.FreyssinetJ
Funding The authors declare that no funds or grants were received for this specific manuscript
*Procent af dagligt referenceindtag Ingredienser: , 74,7% l-karnitin-tartrat, aromer, maltodextrin, farvestof E150d, magnesiumoxid, antiklumpnings middel kiseldioxid, s,demiddel acesulfam K, sucralose, surhedsregulerende midde citronsyre, farvestof carotener, karmin, riboflaviner, E150c, E150d, E133, patent bl,t V, ,indigo carmine, chlorophyll och chlorophylliner, curcumin, anthocyaniner, paprika oleoresin, betanin, vegetabilsk kulstof, 0,03% pyridoxinhydrochlorid vitamin B6
Our findings, combined with existing evidence, suggest that semaglutide and perhaps other GLP1-RAs should be reconceptualized as disease-modifying treatments rather than solely medications for glycaemic control or weight loss, concluded the authors
S2CID 206140413